Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

ENTA Enanta Pharmaceuticals

51.870
-0.550-1.05%
Close 09/30 16:00 ET
51.8700.0000.00%
Post Mkt Price 09/30 16:06 ET
High
54.760
Open
52.580
Turnover
7.20M
Low
51.560
Pre Close
52.420
Volume
137.43K
Market Cap
1.07B
P/E(TTM)
Loss
52wk High
102.000
Shares
20.72M
P/E(Static)
Loss
52wk Low
37.590
Float Cap
862.83M
Bid/Ask %
0.00%
Historical High
127.770
Shs Float
16.63M
Volume Ratio
0.75
Historical Low
14.310
Dividend TTM
--
Div Yield TTM
--
P/B
3.18
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.83%
Amplitude
6.11%
Avg Price
52.377
Lot Size
1
Float Cap
862.83M
Bid/Ask %
0.00%
Historical High
127.770
Shs Float
16.63M
Volume Ratio
0.75
Historical Low
14.310
Dividend TTM
--
P/B
3.18
Dividend LFY
--
Turnover Ratio
0.83%
Amplitude
6.11%
Avg Price
52.377
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.
CEO: Dr. Jay R. Luly
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...